Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

NCT01428492 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: GSK2110183
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Novartis